Treatment of Adamantiades-Behcet disease with systemic interferon alfa

Archives of Dermatology

Volumn 134, Issue 8, 1998, Pages 1010-1016

  Zouboulis, Christos C ^a   Orfanos, Constantin E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHA INTERFERON;

ADULT; ALOPECIA; AMENORRHEA; ARTHRITIS; BEHCET DISEASE; DEPRESSION; DERMATITIS; DIARRHEA; ERYTHEMA NODOSUM; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPOTENSION; INTRAMUSCULAR DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MYOPATHY; PRIORITY JOURNAL; PSYCHOSIS; PUSTULE; REVIEW; SKIN DEFECT; SKIN ULCER; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOPHLEBITIS; UVEITIS; ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; DISEASE COURSE; EVALUATION; META ANALYSIS; MIDDLE AGED; RECURRENT DISEASE; REMISSION; SAFETY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ALOPECIA; ARTHRITIS; BEHCET SYNDROME; CHILD; DISEASE PROGRESSION; EVALUATION STUDIES; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERFERON-ALPHA; LEUKOPENIA; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; SAFETY; TREATMENT OUTCOME; UVEITIS;

EID: 0031595286     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.134.8.1010     Document Type: Review

References (64)

1. International Study Group for Behçet's disease. Criteria for diagnosis of Behçet's disease. Lancet. 1990;335:1078-1080.
2. Zouboulis CC, Kötter I, Djawari D, et al. Epidemiological features of Adamantiades-Behçet's disease in Germany and in Europe. Yonsei Med J. 1997;38:411-422.
3. Adamantiades B. Sur un cas d'iritis à hypopyon récidivant. Ann Oculist (Paris). 1931;168:271-278.
4. Behçet H. Über rezidivierende, aphöthse, durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dematol Wochenschr. 1937; 105:1152-1157.
5. Jorizzo JL, Abernethy JL, White WL, et al. Mucocutaneous criteria for the diagnosis of Behçet's disease: an analysis of clinicopathologic data from multiple international centers. J Am Acad Dermatol. 1995;32:968-976.
6. Kienbaum S, Zouboulis CC, Waibel M, Orfanos CE. Chemotactic neutrophilic vasculitis: a new histopathological pattern of vasculitis found in mucocutaneous lesions of patients with Adamantiades-Behçet's disease. In: Wechsler B, Godeau P, eds. Behçet's Disease. International Congress Series 1037. Amsterdam, the Netherlands: Excerpta Medica; 1993:337-341.
7. Mizuki N, Inoko H, Ohno S. Molecular genetics (HLA) of Behçet's disease. Yonsei Med J. 1997;38:333-349.
8. Lehner T, Lavery E, Smith R, van der Zee R, Mizushima Y, Shinnick T. Association between the 65-kilodalton heat shock protein, streptococcus sanguis, and the corresponding antibodies in Behçet's disease. Infect Immun. 1991;59:1434-1441.
9. Sohn S. Etiopathology of Behçet's disease: herpes simplex virus infection and animal model. Yonsei Med J. 1997;38:359-364.
10. Sakane T, Suzuki N, Nagafuchi H. Etiopathology of Behçet's disease: immunological aspects. Yonsei Med J. 1997;38:350-358.
11. Yazici H. Behçet's syndrome, a personal view. Clin Exp Rheumatol. 1987;5:1-3.
12. Hamza M, Elleuch M, Slim A, Hamzaoui K, Ayed K. Antibodies to herpes simplex virus in patients with Behçet's disease. Clin Rheumatol. 1990;9:498-500.
13. Efthimiou J, Harikumar MK, Knight RA, Snaith ML. Inappropriate peripheral blood lymphocyte responses to herpes viruses in patients with Behçet's syndrome. Immunol Lett. 1984;8:317-318.
14. Young C, Lehner T, Barnes CG. CD4 and CD8 cell responses to herpes simplex virus in Behçet's disease. Clin Exp Immunol. 1988;73:6-10.
15. Eglin RP, Lehner T, Subak-Sharpe JH. Detection of RNA complementary to herpes-simplex virus in mononuclear cells from patients with Behçet's syndrome and recurrent oral ulcers. Lancet. 1982;2:1356-1361.
16. Denman AM, Pelton BK, Hylton W, Malkowsky M, Denning WD. Herpes simplex virus infection and Behçet's syndrome. In: O'Duffy JD, Kokmen E, eds. Behçets Disease: Basic and Clinical Aspects. New York, NY: Marcel Dekker; 1991:415-420.
17. Lee S, Bang D, Cho YH, Lee E-S, Sohn S. Polymerase chain reaction reveals herpes simplex virus DNA in saliva of patients with Behçet's disease. Arch Dermatol Res. 1996;288:179-183.
18. Watanabe K, Ohashi Y. Natural killer cell activity in patients with Behçet's disease. Am J Ophthalmol. 1984;98:813-814.
19. Kaneko F, Takahashi Y, Muramatsu R, et al. Natural killer cell numbers and function in peripheral lymphoid cells in Behçet's disease. Br J Dermatol. 1985;113: 313-318.
20. Hamzaoui K, Ayed K, Hamza M, Touraine JL. Natural killer cells in Behçet's disease. Clin Exp Immunol. 1988;71:126-131.
21. Lee S, Behçet's syndrome. In: Orfanos CE, Stadler R, Gollnick H, eds. Dermatology in Five Continents. Proceedings of the XVII World Congress of Dermatology Berlin, Germany: Springer Verlag; 1988:87-91.
22. Kansu E, Sivri B, Sahin G, et al. Endothelial cell dysfunction in Behçet's disease. In: O'DuffyJD, Kokmen E, eds. Behçet's Disease: Basic and Clinical Aspects. New York NY: Marcel Dekker; 1991:523-530.
23. Bang D, Honma T, Saito T, Nakagawa S, Ueki H, Lee S. Ultrastructure of vascular changes in cutaneous manifestations of Behçet's disease. Acta Derm Venereol. 1988;68:33-40.
24. Tsambaos D, Eichenberg D, Goos M. Behçet's syndrome: treatment with recombinant leucocyte alfa-interferon. Arch Dermatol Res. 1986;278:335-336.
25. Stadler R, Bratzke B, Baumann I. Morbus Behçet und exogenes Interferon: Erfolgreicher Behandlungsversuch mit rekombiniertem α-A-IFN. Hautarzt. 1987; 38:97-100.
26. Stadler R, Bratzke B, Orfanos CE. Therapeutischer Einsatz von α-Interferon bei metastasierendem malignem Melanom, disseminiertem Kaposi-Sarkom und schwerem Morbus Behçet. Hautarzt. 1987;38:453-460.
27. Berman B, Frankfort HM. The human interferon system. Int J Dermatol. 1982; 21:12-18.
28. Zouboulis CC, Treudler R, Orfanos CE. Morbus Adamantiades-Behçet: therapeutischer Einsatz von systemischem rekombinantem Interferon-alfa-2a. Hautarzt. 1993;44:440-445.
29. 2b in Behçet's disease. Arthritis Rheum. 1993;36:1025.
30. Brouty-Boyé D, Zetter BR. Inhibition of cell motility by interferon. Science. 1980; 208:516-518.
31. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor and lymphocyte-induced vascular responses. Cancer Res. 1987;47:5155-5161.
32. Bang D, Lee E-S, Lee S, eds. Reference Index Related to Behçet's Disease. Seoul, Korea: Design Mecca; 1995:1-199.
33. Nakae K, Masaki F, Hashimoto T, Inaba G, Mochizuki M, Sakane T. Recent epidemiological features of Behçet's disease in Japan. In: Wechsler B, Godeau P, eds. Behçet's Disease. Amsterdam, the Netherlands: Excerpta Medica; 1993: 145-151. International Congress Series 1037.
34. Alpsoy E, Yilmaz E, Basaran E. Interferon therapy for Behçet's disease. J Am Acad Dermatol. 1994;31:617-619.
35. Kötter I, Dürk H, Saal JG, Eckstein A, Zierhut M, Fierlbeck G. Interferon α in the treatment of Behçet's disease with erosive arthritis and posterior uveitis: a case report. J Rheumatol. 1994;13:398.
36. Münke MD, Stöckmann F, Ramadoni G. Possible association between Behçet's syndrome and chronic hepatitis C virus infection. N Engl J Med. 1995;332:400-401.
37. Azizerli G, Sarica R, Köse A, et al. The role of interferon alfa-2a in the management of Behçet's disease. Dermatology. 1996;192:239-241.
38. Zouboulis CC, Orfanos CE. Systemic interferon-alfa in the treatment of Adamantiades-Behçet's disease. Rev Rhum Engl Ed. 1996;63:559.
39. Massaro AR, Carnevale A, Laudisio A, Tonali P. L'alfa-interferone nella malattia di Behçet. Riv Neurobiol. 1996;42:477-480.
40. Kötter I, Eckstein A, Stubiger N, Gunaydin I, Zierhut M. Therapy of ocular Behçet's disease with recombinant human interferon-2a. In: Hamza M, ed. Behçet's Disease. Tunis, Tunisia: Pub Adhoua; 1997:447-450.
41. Lumbroso L, Lehoang P, Huong Du LT, Wechsler B. alfa interferon therapy in Behçet disease related uveitis: report of two cases. In: Hamza M, ed. Behçet's Disease. Tunis, Tunisia: Pub Adhoua; 1997:456-457.
42. Azizerli G, Sarica R, Köse A, Övül C, Singer R, Kural Z. The long-term treatment with interferon alfa-2a in Behçet's disease. In: Hamza M, ed. Behçet's Disease. Tunis, Tunisia: Pub Adhoua; 1997:453-457.
43. Grimbacher B, Wenger B, Deibert P, Ness T, Kötter I, Peter HH. Loss of vision and diarrhoea. Lancet. 1997;350:1818.
44. Durand JM, Soubeyrand J. Interferon-2b for refractory ocular Behçet's disease. Lancet. 1994;344:33.
45. Hamuryudan V, Moral F, Yurdakul S, et al. Systemic interferon α2b treatment in Behçet's syndrome. J Rheumatol. 1994;21:1098-1100.
46. Feron EJ, Rothova A, van Hagen PM, Baarsma GS, Suttorp-Schulten MSA. Interferon-α2b for refractory ocular Behçet's disease. Lancet. 1994;343:1428.
47. Dündar S, Demiroglu H, Özcebe O, Özdemir O, Çaliskan S, Eldem B. alfa interferon in Behçet's disease. Hematol Rev. 1996;9:285-290.
48. Sánchez Roman J, Pulido Aguilera MC, Castillo Palma MJ, et al. Utilización de interferón alfa 2r en el tratamiento de las uveitis autoinmunes (primarias o asociadas a enfermedad de Behçet). Rev Clin Esp. 1996;196:293-298.
49. Pivetti-Pezzi P, Accorinti M, Pirraglia MP, Priori R, Valesini G. Interferon α for ocular Behçet's disease. Acta Ophthalmol Scand. 1997;75:720-722.
50. O'Duffy JD, Calamia K, Cohen S, et al. alfa-interferon treatment of Behçet's disease. In: Hamza M, ed. Behçet's Disease. Tunis, Tunisia: Pub Adhoua; 1997: 451-452.
51. Thomas HC, Lok ASF, Carreño V, et al. Comparative study of three doses of interferon-α2a in chronic active hepatitis B. J Viral Hepat. 1994;1:139-148.
52. Antonelli G, Currenti M, Turrizianni O, Dianzani F. Neutralizing antibodies to interferon α: relative frequency in patients treated with different interferon preparations. J Infect Dis. 1991;163:882-885.
53. Fleischmann M, Célérier P, Bernard P, Litoux P, Dreno B. Long-term interferon-alfa therapy induces autoantibodies against epidermis. Dermatology. 1996;192: 50-55.
54. Segawa F, Shimizu Y, Saito E, Kinoshita M. Behçet's disease induced by interferon therapy for chronic myelogenous leukemia. J Rheumatol. 1994;22:1183-1184.
55. Budak-Alpdogan T, Demirçay Z, Alpdogan Ö, et al. Behçet's disease in patients with chronic myelogenous leukemia: possible role of interferon-alfa treatment in the occurrence of Behçet's symptoms. Ann Hematol. 1997;74:45-48.
56. Dippel E, Zouboulis CC, Tebbe B, Orfanos CE. Myopathic syndrome in 4 patients treated with long-term recombinant interferon-α (rIFN-α2a). Arch Dermatol. In press.
57. Edwards BS, Merritt JA, Fuhlbrigge RC, Borden EC. Low doses of interferon alfa result in more effective clinical natural killer cell activation. J Clin Invest. 1985; 75:1908-1913.
58. Hamuryudan V, Yurdakul S, Serdaroglu S, Tüzün Y, Roserikaimer F, Yazici H. Topical alfa interferon in the treatment of oral ulcers in Behçet's syndrome: a preliminary report. Clin Exp Rheumatol. 1990;8:51-54.
59. Hamuryudan V, Yurdakul S, Rosenkaimer F, Yazici H. Inefficacy of topical alfa interferon in the treatment of oral ulcers of Behçet's syndrome: a randomized, double blind trial. Br J Rheumatol. 1991;30:395-396.
60. Mahrle G, Schulze H-J. Recombinant interferon gamma (rIFN-gamma) in dermatology. J Invest Dermatol. 1990;95:1325-1375.
61. Fierlbeck G, Rassner G. Morbus Behçet: Therapie mit rekombinantem Interferon gamma. Akt Dermatol. 1990;16:226-230.
62. Kötter I, Dürk H, Saal J, Fierlbeck G, Pleyer U, Ziehut M. Therapy of Behçet's disease. Ger J Ophthalmol. 1996;5:92-97.
63. Tata F, Gori E, De Bartolomeis AM, Mari MV. Nuove prospettive terapeutiche incorso di malattiadi Behçet: il beta-interferone. Recenti Prog Med. 1988;79:135-137.
64. Kirch W, Dührsen U. Behçet-Syndrom: Therapie mit rekombinantem Interferon-γ. Dtsch Med Wochenschr. 1990;115:357.